Co-Diagnostics, Inc. has made a strategic move by entering into a loan agreement with J.J. Astor & Co., securing up to $3.1 million in funding. This agreement is significant as it aims to enhance the company's working capital, crucial for its operations in the surgical and medical instruments sector.
On October 9, 2026, the company executed a Loan Agreement with the lender, which initially funded $2.1 million. In exchange, Co-Diagnostics issued a senior secured convertible installment promissory note worth $2.835 million. The company may borrow an additional $1.0 million, subject to specific conditions outlined in the agreement.
Co-Diagnostics, based in Salt Lake City, Utah, operates in the surgical and medical instruments and apparatus sector. The company trades on the Nasdaq under the ticker symbol CODX. The recent filing indicates that the funds will be used for general working capital purposes, which may help the company navigate its financial landscape more effectively.
According to the filing, the loan agreement includes a requirement for Co-Diagnostics to maintain a minimum cash balance of $250,000 while the notes are outstanding. The repayment structure involves 30 weekly installments, with the notes secured by a lien on substantially all the company's assets.
In the event of a default, the outstanding balance would become immediately due, and the principal amount would increase significantly. The agreement also allows the lender to convert the notes into shares of common stock at a predetermined conversion price.
Co-Diagnostics also issued 600,000 shares of common stock as commitment shares to the lender, with provisions for additional shares if the stock price falls below a specified threshold. This aspect of the agreement highlights the company's commitment to ensuring the lender's interests are protected while providing the necessary capital for its operations.
The loan agreement stipulates that Co-Diagnostics must file a preliminary proxy statement and hold a stockholder meeting within a specified timeframe, indicating that shareholder approval may be necessary for certain aspects of the agreement.
As Co-Diagnostics moves forward with this loan agreement, it will be essential for the company to manage its financial obligations effectively. The surgical and medical instruments industry is competitive, and how Co-Diagnostics leverages this funding could influence its market position.
Details regarding the next steps in this process were not specified in the filing. However, the company is expected to keep its stakeholders informed as it navigates this new financial landscape.